LT3773715T - Mirikizumabas, skirtas naudoti gydant opinį kolitą - Google Patents
Mirikizumabas, skirtas naudoti gydant opinį kolitąInfo
- Publication number
- LT3773715T LT3773715T LTEPPCT/US2019/024633T LTUS2019024633T LT3773715T LT 3773715 T LT3773715 T LT 3773715T LT US2019024633 T LTUS2019024633 T LT US2019024633T LT 3773715 T LT3773715 T LT 3773715T
- Authority
- LT
- Lithuania
- Prior art keywords
- mirikizumab
- treatment
- ulcerative colitis
- ulcerative
- colitis
- Prior art date
Links
- 206010009900 Colitis ulcerative Diseases 0.000 title 1
- 201000006704 Ulcerative Colitis Diseases 0.000 title 1
- 229950009792 mirikizumab Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650314P | 2018-03-30 | 2018-03-30 | |
| PCT/US2019/024633 WO2019191464A1 (en) | 2018-03-30 | 2019-03-28 | Methods of treating ulcerative colitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3773715T true LT3773715T (lt) | 2024-06-25 |
Family
ID=66429483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2019/024633T LT3773715T (lt) | 2018-03-30 | 2019-03-28 | Mirikizumabas, skirtas naudoti gydant opinį kolitą |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US12152072B2 (enExample) |
| EP (2) | EP3773715B1 (enExample) |
| JP (4) | JP7119114B2 (enExample) |
| KR (1) | KR102552693B1 (enExample) |
| CN (1) | CN111936165A (enExample) |
| AU (2) | AU2019243283C1 (enExample) |
| BR (1) | BR112020018099A2 (enExample) |
| CA (1) | CA3095297A1 (enExample) |
| DK (1) | DK3773715T3 (enExample) |
| EA (1) | EA202091989A1 (enExample) |
| ES (1) | ES2983809T3 (enExample) |
| FI (1) | FI3773715T3 (enExample) |
| HR (1) | HRP20240904T1 (enExample) |
| HU (1) | HUE067445T2 (enExample) |
| IL (2) | IL277514B2 (enExample) |
| LT (1) | LT3773715T (enExample) |
| MA (1) | MA52216B1 (enExample) |
| MD (1) | MD3773715T2 (enExample) |
| MX (1) | MX2020010269A (enExample) |
| MY (1) | MY202368A (enExample) |
| PL (1) | PL3773715T3 (enExample) |
| PT (1) | PT3773715T (enExample) |
| RS (1) | RS65661B1 (enExample) |
| SG (1) | SG11202009526RA (enExample) |
| SI (1) | SI3773715T1 (enExample) |
| TW (2) | TWI837532B (enExample) |
| UA (1) | UA128578C2 (enExample) |
| WO (1) | WO2019191464A1 (enExample) |
| ZA (1) | ZA202005388B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020279987A1 (en) | 2019-05-23 | 2021-11-18 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
| KR20220141847A (ko) * | 2020-02-14 | 2022-10-20 | 얀센 바이오테크 인코포레이티드 | 항-il12/il23 항체로 궤양성 결장염을 치료하는 안전하고 효과적인 방법 |
| CA3183927A1 (en) | 2020-05-21 | 2021-11-25 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| JP7423815B2 (ja) * | 2020-10-20 | 2024-01-29 | セトラスホールディングス株式会社 | 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム |
| TW202241506A (zh) * | 2021-01-06 | 2022-11-01 | 美商艾伯維有限公司 | 治療克羅恩氏病及潰瘍性結腸炎之方法 |
| JP2024520202A (ja) * | 2021-05-20 | 2024-05-22 | ヤンセン バイオテツク，インコーポレーテツド | Ｉｌ－２３に対する抗体及びｔｎｆアルファに対する抗体の組み合わせ療法を用いた炎症性腸疾患を治療する方法 |
| EP4347018A1 (en) * | 2021-05-28 | 2024-04-10 | Eli Lilly and Company | Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis |
| WO2024110898A1 (en) * | 2022-11-22 | 2024-05-30 | Janssen Biotech, Inc. | Method of treating ulcerative colitis with anti-il23 specific antibody |
| KR20250156783A (ko) | 2023-03-10 | 2025-11-03 | 일라이 릴리 앤드 캄파니 | 궤양성 결장염을 치료하는 방법 |
| TW202500185A (zh) * | 2023-06-16 | 2025-01-01 | 大陸商信達生物製藥（蘇州）有限公司 | 重組抗白介素２３ｐ１９亞基抗體在治療炎症性腸病中的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20130400T1 (en) * | 2005-06-30 | 2013-06-30 | Janssen Biotech, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
| DK2548577T3 (en) | 2005-12-29 | 2017-03-13 | Janssen Biotech Inc | HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, PROCEDURES AND APPLICATIONS |
| US8293883B2 (en) | 2007-02-23 | 2012-10-23 | Schering Corporation | Engineered anti-IL-23P19 antibodies |
| US20110212104A1 (en) * | 2008-11-03 | 2011-09-01 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| JP6126532B2 (ja) * | 2010-11-04 | 2017-05-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗ｉｌ−２３抗体 |
| JOP20140049B1 (ar) | 2013-03-08 | 2021-08-17 | Lilly Co Eli | أجسام مضادة ترتبط بـ il-23 |
| US20170002060A1 (en) * | 2014-01-08 | 2017-01-05 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
| MX2020009265A (es) * | 2018-03-05 | 2020-10-01 | Janssen Biotech Inc | Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23. |
-
2019
- 2019-03-27 TW TW110139868A patent/TWI837532B/zh active
- 2019-03-27 TW TW108110767A patent/TWI744617B/zh active
- 2019-03-28 RS RS20240698A patent/RS65661B1/sr unknown
- 2019-03-28 US US16/981,915 patent/US12152072B2/en active Active
- 2019-03-28 SI SI201930750T patent/SI3773715T1/sl unknown
- 2019-03-28 HR HRP20240904TT patent/HRP20240904T1/hr unknown
- 2019-03-28 CN CN201980023563.3A patent/CN111936165A/zh active Pending
- 2019-03-28 JP JP2020552872A patent/JP7119114B2/ja active Active
- 2019-03-28 KR KR1020207027982A patent/KR102552693B1/ko active Active
- 2019-03-28 WO PCT/US2019/024633 patent/WO2019191464A1/en not_active Ceased
- 2019-03-28 EP EP19722256.5A patent/EP3773715B1/en active Active
- 2019-03-28 PL PL19722256.5T patent/PL3773715T3/pl unknown
- 2019-03-28 ES ES19722256T patent/ES2983809T3/es active Active
- 2019-03-28 UA UAA202005571A patent/UA128578C2/uk unknown
- 2019-03-28 LT LTEPPCT/US2019/024633T patent/LT3773715T/lt unknown
- 2019-03-28 PT PT197222565T patent/PT3773715T/pt unknown
- 2019-03-28 DK DK19722256.5T patent/DK3773715T3/da active
- 2019-03-28 FI FIEP19722256.5T patent/FI3773715T3/fi active
- 2019-03-28 BR BR112020018099-8A patent/BR112020018099A2/pt unknown
- 2019-03-28 SG SG11202009526RA patent/SG11202009526RA/en unknown
- 2019-03-28 IL IL277514A patent/IL277514B2/en unknown
- 2019-03-28 IL IL312807A patent/IL312807B2/en unknown
- 2019-03-28 MD MDE20210135T patent/MD3773715T2/ro unknown
- 2019-03-28 EA EA202091989A patent/EA202091989A1/ru unknown
- 2019-03-28 CA CA3095297A patent/CA3095297A1/en active Pending
- 2019-03-28 MX MX2020010269A patent/MX2020010269A/es unknown
- 2019-03-28 MY MYPI2020004942A patent/MY202368A/en unknown
- 2019-03-28 HU HUE19722256A patent/HUE067445T2/hu unknown
- 2019-03-28 AU AU2019243283A patent/AU2019243283C1/en active Active
- 2019-03-28 MA MA52216A patent/MA52216B1/fr unknown
- 2019-03-28 EP EP23215626.5A patent/EP4327866B1/en active Active
-
2020
- 2020-08-28 ZA ZA2020/05388A patent/ZA202005388B/en unknown
-
2022
- 2022-08-03 JP JP2022123689A patent/JP7331219B2/ja active Active
-
2023
- 2023-08-09 JP JP2023130117A patent/JP7571225B2/ja active Active
- 2023-10-11 AU AU2023248103A patent/AU2023248103A1/en active Pending
-
2024
- 2024-10-09 JP JP2024176901A patent/JP2025020134A/ja active Pending
- 2024-10-16 US US18/917,597 patent/US20250034243A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3773715T (lt) | Mirikizumabas, skirtas naudoti gydant opinį kolitą | |
| IL269354A (en) | Compounds useful in the treatment or prevention of prmt5-mediated disorder | |
| GB201614522D0 (en) | Use of cannabinoids in the treatment of multiple myeloma | |
| GB201411496D0 (en) | Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy | |
| GB201400442D0 (en) | Compositions for use in the treatment of ulcerative colitis | |
| IL268210A (en) | Use of gaboxadol in the treatment of tinnitus | |
| PL3331610T3 (pl) | Środki do zastosowania w leczeniu glejaka | |
| IL272962A (en) | Use of gaboksadol for the treatment of anesthesia | |
| IL279917A (en) | Treating ulcerative colitis with brazikumab | |
| PL3580182T3 (pl) | Uzdatnianie wody | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| IL259205B (en) | Glycolipid compounds and their uses in the treatment of tumors | |
| LT3548006T (lt) | Kompozicija, skirta žarnyno pakitimams gydyti | |
| GB201609851D0 (en) | Water treatment | |
| GB201617715D0 (en) | Methods for the treatment and prevention of ebola | |
| HK40050836A (en) | Treating ulcerative colitis with brazikumab | |
| ZA201703047B (en) | The treatment of water | |
| ZA201804726B (en) | Water treatment facility | |
| IL255001A0 (en) | Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of negative side effects of chemotherapy | |
| ZA201706977B (en) | Water treatment | |
| ZA201702594B (en) | Water treatment | |
| GB201614103D0 (en) | Water treatment | |
| HK40000513A (en) | Formulations and methods for treating ulcerative colitis | |
| GB201617591D0 (en) | Methods for the treatment and prevention of ebola |